Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
1999-11-01
2003-07-01
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S234100, C435S069100, C435S006120, C514S04400A, C536S023500
Reexamination Certificate
active
06585975
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to the use of Salmonella vectors in vaccination methods against Helicobacter infection.
Helicobacter is a genus of spiral, gram-negative bacteria that colonize the gastrointestinal tracts of mammals. Several species colonize the stomach, most notably
H. pylori, H. heilmanii, H. felis,
and
H. mustelae.
Although
H. pylori
is the species most commonly associated with human infection,
H. heilmanii
and
H. felis
have also been isolated from humans, but at lower frequencies than
H. pylori.
Helicobacter infects over 50% of adult populations in developed countries and nearly 100% in developing countries and some Pacific rim countries, making it one of the most prevalent infections worldwide.
Helicobacter is routinely recovered from gastric biopsies of humans with histological evidence of gastritis and peptic ulceration. Indeed,
H. pylori
is now recognized as an important pathogen of humans, in that the chronic gastritis it causes is a risk factor for the development of peptic ulcer diseases and gastric carcinoma. It is thus highly desirable to develop safe and effective methods for preventing and treating Helicobacter infection.
SUMMARY OF THE INVENTION
The invention provides a method of inducing an immune response against Helicobacter in a mammal. This method involves mucosally (e.g., orally) administering to a mammal (e.g., a human) an attenuated Salmonella (e.g.,
S. typhi
(e.g., CVD908-htrA or CVD908) or
S. typhimurium
(e.g., BRD509 or BRD807)) vector including a nucleic acid molecule encoding a Helicobacter antigen (e.g., a urease, a urease subunit, or an immunogenic fragment thereof), and parenterally administering to the mammal a Helicobacter antigen (e.g., a urease, a urease subunit, or an immunogenic fragment thereof), optionally, in association with an adjuvant, such as an aluminum compound (e.g., alum). The nucleic acid molecule encoding the Helicobacter antigen can be under the control of a promoter, such as an htrA or a nirB promoter. The antigen used in the mucosal administration can be different from, cross-reactive with, or, preferably, identical to the parenterally administered antigen. In a preferred embodiment, the mucosal administration primes an immune response to an antigen, and the parenteral administration boosts an immune response to the antigen. A mammal treated according to the method of the invention can be at risk of developing, but not have, a Helicobacter infection, or can have a Helicobacter infection. That is, the method can be used to prevent or to treat Helicobacter infection.
The invention also provides an attenuated Salmonella (e.g.,
S. typhi
(e.g., CVD908-htrA or CVD908) or
S. typhimurium
(e.g., BRD509 or BRD807)) vector including a nucleic acid molecule encoding a Helicobacter antigen, e.g., a urease, a urease subunit, or an immunogenic fragment thereof, expressed as a fission protein that can be selectively targeted to the outer membrane or secreted from the cell. The nucleic acid molecule encoding the Helicobacter antigen can be under the control of a promoter, such as an htrA or a nirB promoter.
Other features and advantages of the invention will be apparent from the following detailed description, the drawings, and the claims.
REFERENCES:
patent: 4888170 (1989-12-01), Curtiss, III
patent: 5538729 (1996-07-01), Czinn et al.
patent: 5547664 (1996-08-01), Charles
patent: 5683700 (1997-11-01), Charles et al.
patent: 5783196 (1998-07-01), Noriega et al.
patent: 5843426 (1998-12-01), Miller et al.
patent: 5843460 (1998-12-01), Labigne et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 5888799 (1999-03-01), Curtiss, III
patent: 5928865 (1999-07-01), Covacci
patent: 5985631 (1999-11-01), Soman et al.
patent: 6005090 (1999-12-01), Doidge et al.
patent: 6024961 (2000-02-01), Curtiss, III et al.
patent: 6030624 (2000-02-01), Russell
patent: 6126938 (2000-10-01), Guy et al.
patent: 6383496 (2002-05-01), Curtiss, III et al.
patent: 835928 (1998-04-01), None
patent: 9215688 (1992-09-01), None
patent: 9318150 (1993-09-01), None
patent: 9522987 (1995-08-01), None
patent: 9640893 (1996-12-01), None
patent: 9702835 (1997-01-01), None
patent: WO 99/21959 (1999-05-01), None
Goldman, B.S. et al, Asdtr. Gen. Meet. Am. Soc. Microbiol., vol. 91(0), p. 229, 1991.*
Corthesy-Theulaz et al, Vaccine Weekly, PN/A, Mar. 23, 1998, (abstract), 1998.*
Dore-Davin et al, Gastroenterology, vol. 110(4), May, p. A898 (abstract), 1996.*
Haas, R et al, Biologicals, vol. 25, pp. 175-177, 1997.*
Corthesy-Theulaz et al, Gastroenterology, vol. 112(4 suppl), p. A953, 1997.*
Corthesy-Theulaz, I.E. et al, Infection Immunity, Feb., vol. 6692), pp. 581-586, 1998.*
Hartman, AB et al, Infection Immunity, Feb., vol. 62(2), pp. 412-420, (abstract), 1994.*
Keren, DF et al, Infection Immunity, Apr., vol. 56(4), pp. 919-915, (abstract), 1988.*
Kwon, D.H. et al, Gut vol. 41(suppl 1), p. A15, 1997.*
Gomez-Durarte, OG et al, Vaccine, Mar., vol. 16(5), pp. 460-467,(abstract), 1998.*
Gomez-Durate, OG et al, Gut, vol. 41(suppl 1), p. A59-A60, (abstract), 1997.*
Lugtenburg, T. Safety and efficacy of oral or combined oral and parenteral immunization with inactivated or live avirulent bacteria againstSalmonella typhimuriumin the calf., Ludwig-Maximilians Universitat, Munchen (abstrct of thesis), 1981.*
Tacket, CO et al, Vaccine Weekley, pN/A, Mar. 17,Salmonella typhi“Safety of live oralsalmonella typhivaccine strains with deletions in htrA and aroCaroD and Immune response in Humans.” (abstract), 1997.*
Tacket, C.O. et al, Infection Immunity, Feb., vol. 65(2), pp. 452-456, 1997.*
Hone, D.M. et al, J. Clin. Invest., vol. 90, pp. 412-420, 1992.*
Gonzalez, C et al, J. Infectious Diseases, vol. 169, pp. 927-931, 1994.*
Tomb, J.F et al, Nature, vol. 388, Aug., pp. 539-547, 1997.*
Torres, JF et al, Infection Immunity, vol. 63(12), pp. 4619-4627, Dec., 1995.*
Szostak, M.P. et al, Behring Inst. Mitt, No. 98, pp. 191-196, 1997.*
Chen, M et al, Gastroenterology, vol. 104(4), Apr., p. A681, 1993.*
Anderson et al., “Delivery of the Pertactin/P.69 Polypeptide ofBordetella pertussisUsing an AttenuatedSalmonella typhimuriumVaccine Strain: Expression Levels and Immune Response,” Vaccine 14:1384-1390 (1996).
Ward et al., “Immunogenicity of aSalmonella typhimurium aroA aroDVaccine Expressing a Nontoxic Domain ofClostridium difficileToxin A,” Infection and Immunity 67:2145-2152 (1999).
Lee et al., “Immunization of Rhesus Monkeys with Mucosal Prime, Parenteral Boost Strategy Protects against Infection withHelicobacter pylori,”Abstract-Vaccine17:3072-3082 (1999).
Fulginiti, J et al , Oral immunization of mice with live attenuated S.typhimurium expressing H.pylori urease, Abstracts of papers presented at the meeting on Molecular approasches to the control of Infectious diseases, 1995, p. 27, Cold Spring Harbor.*
Krachenbuhl, JP, Infectious Disease Weekly, pN/A, Jul. 8, 1996, Vaccine Development “Vaccines of Tomorrow: The Hope of Science.”
Freeman Donna
Kleanthous Harold
Lee Cynthia K.
Londono-Arcila Patricia
Monath Thomas P.
Acambis Inc.
Clark & Elbing LLP
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Use of Salmonella vectors for vaccination against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of Salmonella vectors for vaccination against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Salmonella vectors for vaccination against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3033882